Controlled Trial of the Effects of 1,25-Dihydroxycholecalciferol in Patients Treated with Regular Dialysis

Tomas Berl,Arnold S. Berns,William E. Huffer,Allen C. Alfrey,Claude D. Arnaud,Robert R. Schrier
DOI: https://doi.org/10.1159/000403274
2024-05-18
Contributions to Nephrology
Abstract:In a double-blind controlled study, 15 patients received 1,25-dihydroxycholecalciferol (1,25[OH]2D3) (0.5-1.5 microgram/day) and 16 patients received vitamin D3 (D3) (400-1,200 IU/day). The patients receiving 1,25(OH)2D3 had a rise in mean serum calcium concentration from 9.05 +/- 0.15 to 10.25 +/- 0.20 mg/dl (p less than .001) with a return to 9.37 +/- 0.16 (p less than .001) in the post-control period; however, hypercalcemia (greater than 11.5 mg/dl) occurred in 5 of 15 patients. Likewise, patients who received 1,25(OH)2D3 but not those given D3 had a reversible decrease in immunoreactive parathyroid levels. 9 of 12 patients given D3 had serial iliac crest bipsies showing histologic deterioration, while 6 of 7 patients who received 1,25(OH)2D3 were improved or unchanged (p less than 0.025). Bone mineral and calcium content decreased in patients on D3 (p less than .05) but not in those on 1,25(OH)2D3. We conclude that the administration of 1,25(OH)2D3 to dialysis patients: (1) has a calcemic effect. (2) decreases levels of immunoreactive parathyroid hormone, and (3) is associated with histologic improvement in bone disease.
urology & nephrology
What problem does this paper attempt to address?
The paper aims to explore the short-term effects of 1,25-dihydroxyvitamin D (1,25(OH)₂D₃) in long-term dialysis patients. The study background indicates that osteodystrophy and its related symptoms are one of the major health issues for patients undergoing long-term hemodialysis. Although changes in blood calcium and phosphorus levels can be corrected through dietary adjustments or changes in dialysis calcium concentration combined with phosphate binders, vitamin D is crucial for bone remineralization. However, end-stage renal disease patients have a poor response to vitamin D, possibly because they cannot synthesize the bioactive form of this vitamin—1,25(OH)₂D₃. Therefore, this study aims to evaluate the efficacy of 1,25(OH)₂D₃ in a large, unselected population of dialysis patients through a double-blind controlled trial, particularly its effects on blood calcium levels, immunoreactive parathyroid hormone (iPTH) levels, and bone histopathology. In short, the core issue of this study is to assess whether 1,25(OH)₂D₃ can effectively improve the osteodystrophy condition in dialysis patients and to understand its potential side effects.